+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Erythropoietin Drugs Market Research Report by Drug Class, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4989689
  • Report
  • July 2021
  • Region: Global
  • 184 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Erythropoietin Drugs Market will Grow to USD 10,503.34 Million by 2026, at a CAGR of 8.05%

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira Inc.
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • MORE
The Global Erythropoietin Drugs Market size was estimated at USD 6,598.13 Million in 2020 and expected to reach USD 7,107.38 Million in 2021, at a Compound Annual Growth Rate (CAGR) 8.05% to reach USD 10,503.34 Million by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Erythropoietin Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the Erythropoietin Drugs Market was studied across Biologics and Biosimilars.
  • Based on Product, the Erythropoietin Drugs Market was studied across Darbepoetin-alfa, Epoetin-alfa, and Epoetin-beta.
  • Based on Application, the Erythropoietin Drugs Market was studied across Cancer, Hematology, Neurology, and Renal Diseases.
  • Based on Region, the Erythropoietin Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Erythropoietin Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Erythropoietin Drugs Market, including Amgen Inc., Biocon Limited, Celltrion, Inc., Hospira Inc., Intas Pharmaceuticals, Johnson & Johnson, LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Roche Holding AG, and Teva Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Erythropoietin Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Erythropoietin Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Erythropoietin Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Erythropoietin Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Erythropoietin Drugs Market?
6. What is the market share of the leading vendors in the Global Erythropoietin Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Erythropoietin Drugs Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira Inc.
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Product Outlook
3.5. Application Outlook
3.6. Region Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of HIV, cancer, and ESRD globally
5.1.1.2. Increasing development of synthetic forms of ESRD with enhanced recombinant DNA technology
5.1.2. Restraints
5.1.2.1. High cost EPO drugs
5.1.3. Opportunities
5.1.3.1. Introduction of novel drugs and cost-efficient biosimilar formulations
5.1.3.2. Ongoing robust research and development activities to develop innovative molecules
5.1.4. Challenges
5.1.4.1. Stringent regulatory protocols for drug approval
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Erythropoietin Drugs Market, by Drug Class
6.1. Introduction
6.2. Biologics
6.3. Biosimilars

7. Erythropoietin Drugs Market, by Product
7.1. Introduction
7.2. Darbepoetin-alfa
7.3. Epoetin-alfa
7.4. Epoetin-beta

8. Erythropoietin Drugs Market, by Application
8.1. Introduction
8.2. Cancer
8.3. Hematology
8.4. Neurology
8.5. Renal Diseases

9. Americas Erythropoietin Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Erythropoietin Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Thailand

11. Europe, Middle East & Africa Erythropoietin Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Amgen Inc.
13.2. Biocon Limited
13.3. Celltrion, Inc.
13.4. Hospira Inc.
13.5. Intas Pharmaceuticals
13.6. Johnson & Johnson
13.7. LG Life Sciences Ltd.
13.8. Ranbaxy Laboratories Ltd.
13.9. Roche Holding AG
13.10. Teva Pharmaceutical Industries Ltd.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 3. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY PRODUCT, 2020 (USD MILLION)
FIGURE 4. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 5. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 6. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 7. GLOBAL ERYTHROPOIETIN DRUGS MARKET: MARKET DYNAMICS
FIGURE 8. GLOBAL ERYTHROPOIETIN DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 9. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 10. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 12. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2026 (USD MILLION)
FIGURE 13. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 14. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY BIOSIMILARS, 2018-2026 (USD MILLION)
FIGURE 15. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 16. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (%)
FIGURE 17. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (USD MILLION)
FIGURE 18. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY PRODUCT, 2026
FIGURE 19. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DARBEPOETIN-ALFA, 2018-2026 (USD MILLION)
FIGURE 20. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DARBEPOETIN-ALFA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 21. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY EPOETIN-ALFA, 2018-2026 (USD MILLION)
FIGURE 22. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY EPOETIN-ALFA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 23. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY EPOETIN-BETA, 2018-2026 (USD MILLION)
FIGURE 24. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY EPOETIN-BETA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 25. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 26. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY APPLICATION, 2026
FIGURE 28. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY CANCER, 2018-2026 (USD MILLION)
FIGURE 29. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 30. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2026 (USD MILLION)
FIGURE 31. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 32. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY NEUROLOGY, 2018-2026 (USD MILLION)
FIGURE 33. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 34. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY RENAL DISEASES, 2018-2026 (USD MILLION)
FIGURE 35. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 36. AMERICAS ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 37. ARGENTINA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 38. BRAZIL ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 39. CANADA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 40. MEXICO ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 41. UNITED STATES ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 42. ASIA-PACIFIC ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 43. AUSTRALIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 44. CHINA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 45. INDIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 46. INDONESIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 47. JAPAN ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 48. MALAYSIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 49. PHILIPPINES ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 50. SINGAPORE ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 51. SOUTH KOREA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 52. THAILAND ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 54. FRANCE ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 55. GERMANY ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 56. ITALY ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 57. NETHERLANDS ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 58. QATAR ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. RUSSIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. SAUDI ARABIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. SOUTH AFRICA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. SPAIN ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. UNITED ARAB EMIRATES ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. UNITED KINGDOM ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. GLOBAL ERYTHROPOIETIN DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 66. GLOBAL ERYTHROPOIETIN DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 67. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ERYTHROPOIETIN DRUGS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL ERYTHROPOIETIN DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY DARBEPOETIN-ALFA, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY EPOETIN-ALFA, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY EPOETIN-BETA, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL ERYTHROPOIETIN DRUGS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. AMERICAS ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 17. ARGENTINA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 18. BRAZIL ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 19. CANADA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 20. MEXICO ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 21. UNITED STATES ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 22. ASIA-PACIFIC ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 23. AUSTRALIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 24. CHINA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 25. INDIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 26. INDONESIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. JAPAN ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. MALAYSIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. PHILIPPINES ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. SINGAPORE ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. SOUTH KOREA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. THAILAND ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. EUROPE, MIDDLE EAST & AFRICA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. FRANCE ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. GERMANY ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. ITALY ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. NETHERLANDS ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. QATAR ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. RUSSIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. SAUDI ARABIA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. SOUTH AFRICA ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. SPAIN ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. UNITED ARAB EMIRATES ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. UNITED KINGDOM ERYTHROPOIETIN DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. GLOBAL ERYTHROPOIETIN DRUGS MARKET: SCORES
TABLE 46. GLOBAL ERYTHROPOIETIN DRUGS MARKET: BUSINESS STRATEGY
TABLE 47. GLOBAL ERYTHROPOIETIN DRUGS MARKET: PRODUCT SATISFACTION
TABLE 48. GLOBAL ERYTHROPOIETIN DRUGS MARKET: RANKING
TABLE 49. GLOBAL ERYTHROPOIETIN DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 50. GLOBAL ERYTHROPOIETIN DRUGS MARKET: MERGER & ACQUISITION
TABLE 51. GLOBAL ERYTHROPOIETIN DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 52. GLOBAL ERYTHROPOIETIN DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 53. GLOBAL ERYTHROPOIETIN DRUGS MARKET: INVESTMENT & FUNDING
TABLE 54. GLOBAL ERYTHROPOIETIN DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 55. GLOBAL ERYTHROPOIETIN DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira Inc.
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • LG Life Sciences Ltd.
  • Ranbaxy Laboratories Ltd.
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll